Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2018, Article ID 4879406, 11 pages
https://doi.org/10.1155/2018/4879406
Clinical Study

Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine

1Department of Surgery, Innoshima-Ishikai Hospital, Innoshima, Onomichi, Hiroshima 722-2211, Japan
2Cell-Medicine, Inc., 2-1-6 Sengen, Tsukuba, Ibaraki 305-0074, Japan

Correspondence should be addressed to Fumito Kuranishi; pj.en.nco.hcaeb@iakihsi

Received 28 September 2017; Revised 12 December 2017; Accepted 20 December 2017; Published 22 January 2018

Academic Editor: Mattia Capulli

Copyright © 2018 Fumito Kuranishi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. NCCN, “NCCN Clinical Practice Guidelines in Oncology, Breast Cancer, Version 3.2015,” Tech. Rep., NCCN.org, 2015. View at Google Scholar
  2. M. Yong, A. Ø. Jensen, J. B. Jacobsen, M. Nørgaard, J. P. Fryzek, and H. T. Sørensen, “Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007),” Breast Cancer Research and Treatment, vol. 129, no. 2, pp. 495–503, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Lipton, R. J. Cook, P. Major, M. R. Smith, and R. E. Coleman, “Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity,” The Oncologist, vol. 12, no. 9, pp. 1035–1043, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Howell, J. Cuzick, M. Baum et al., “Results of the ATAC (anastrozole, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer,” The Lancet, vol. 365, no. 9453, pp. 60–62, 2005. View at Publisher · View at Google Scholar
  5. G. R. Mundy, “Mechanisms of bone metastasis,” Cancer, vol. 80, no. 8, pp. 1546–1556, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. B. G. Peng, S. Q. Liu, M. Kuang et al., “Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma,” Japanese Journal of Cancer Research, vol. 93, no. 4, pp. 363–368, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Kuang, B. G. Peng, M. D. Lu et al., “Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma,” Clinical Cancer Research, vol. 10, no. 5, pp. 1574–1579, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Ishikawa, K. Tsuboi, T. Yamamoto et al., “Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients,” Cancer Science, vol. 98, no. 8, pp. 1226–1233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Muragaki, T. Maruyama, H. Iseki et al., “Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma,” Journal of Neurosurgery, vol. 115, no. 2, pp. 248–255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Ishikawa, Y. Muragaki, T. Yamamoto et al., “Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma,” Journal of Neurosurgery, vol. 121, no. 3, pp. 543–553, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Sakamoto, E. Ishikawa, T. Yamamoto et al., “Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma,” Neurologia medico-chirurgica, vol. 51, no. 4, pp. 319–325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Todoroki, T. Kondo, S. Sugahara, Y. Morishita, K. Mori, and T. Ohno, “Long-term survivor of relapsed MFH on the thigh treated with autologous formalin-fixed tumor vaccine (AFTV) combined with limb-sparing surgery and radiotherapy,” World Journal of Surgical Oncology, vol. 9, article no. 96, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Inui and T. Ohno, “Autologous formalin-fixed tumor vaccine suppressedre-recurrence of HCV-related hepatocellularcarcinoma following 29 unsuccessful treatments withextensive conventional therapy: a case report,” World Journal of Surgical Oncology, p. 144, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Chen and T. Ohno, “Recurrent peritoneal serous carcinoma that was unmanageable with paclitaxel-carboplatin therapy responded to autologous formalin-fixed tumor vaccine,” Clinical Case Reports, vol. 3, no. 10, pp. 823–826, 2015. View at Publisher · View at Google Scholar
  15. T. Miyoshi, T. Kataoka, A. Asahi et al., “A transient increase and subsequent sharp decrease of chemo-refractory liver-metastasized uterine cervical small cell carcinoma to autologous formalin-fixed tumor vaccine plus anti-PD-1 antibody,” Clinical Case Reports, vol. 4, no. 7, pp. 687–691, 2016. View at Publisher · View at Google Scholar
  16. T. Miyoshi, T. Kashiwabara, A. Asahi et al., “Complete remission of chemo-refractory multiple-metastatic upper tract urothelial carcinoma by autologous formalin-fixed tumor vaccine,” Clinical Case Reports, vol. 5, no. 11, pp. 1780–1784, 2017. View at Publisher · View at Google Scholar
  17. Y. Imaoka, F. Kuranishi, T. Miyazaki, H. Yasuda, and T. Ohno, “Long-lasting complete response status of advanced stage IV gall bladder cancer and colon cancer after combined treatment including autologous formalin-fixed tumor vaccine: two case reports,” World Journal of Surgical Oncology, vol. 15, no. 1, 2017. View at Publisher · View at Google Scholar
  18. I. Kawashima, Y. Kawashima, Y. Matsuoka et al., “Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3,” Clinical Case Reports, vol. 3, no. 6, pp. 444–447, 2015. View at Publisher · View at Google Scholar
  19. M. Koizumi, M. Yoshimoto, F. Kasumi, and E. Ogata, “Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients,” Annals of Oncology, vol. 14, no. 8, pp. 1234–1240, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Kuranishi and T. Ohno, “Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report,” World Journal of Surgical Oncology, vol. 11, article no. 127, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Trotti, R. Byhardt, J. Stetz et al., “Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy,” International Journal of Radiation Oncology, Biology, and Physics, vol. 47, no. 1, pp. 13–47, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. U. Falkmer, J. Järhult, P. Wersäll, and E. Cavallin-Ståhl, “A systematic overview of radiation therapy effects in skeletal metastases,” Acta Oncologica, vol. 42, no. 5-6, pp. 620–633, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Di Lascio and O. Pagani, “Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?” Breast Care, vol. 9, no. 1, pp. 7–14, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Kobrinsky, E. Andreopoulou, K. Mourtzikos, and F. Muggia, “Documentation of complete response in metastatic breast cancer to liver and bone achieved with trastuzumab and pegylated liposomal doxorubicin,” Clinical Medicine: Oncology, vol. 2, pp. 469-470, 2008. View at Google Scholar · View at Scopus
  25. A. B. Sharabi, M. Lim, T. L. DeWeese, and C. G. Drake, “Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy,” The Lancet Oncology, vol. 16, no. 13, pp. e498–e509, 2015. View at Publisher · View at Google Scholar · View at Scopus